One of Gen-Probe’s key growth strategies is to apply the Company’s proprietary molecular diagnostic technologies to new markets where there are important unmet medical needs and attractive commercial opportunities. Oncology is expected to be one of these markets, with growth driven by an aging population and the rapid discovery of new genetic biomarkers. The Company’s oncology efforts are built around the highly specific prostate cancer gene PCA3. Gen-Probe’s PCA3 program moved ahead on several fronts during 2006.